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Background The role of sublobar resection in the treatment of pulmonary typical carcinoids is 
controversial. This study aims to compare long-term outcomes between sublobar and lobar resections in 
patients with peripheral typical carcinoid. 
Methods We retrospectively compared consecutive patients who underwent curative sublobar resection to 
lobectomy for cT1-3N0M0 peripheral pulmonary typical rcinoid in eight centers between 2000-2015. 
Primary outcomes were rates and patterns of recurrence and overall survival. Cox regression modeling 
was performed to identify factors influencing overall survival and recurrence. Propensity score analysis 
was done and overall survival was compared between the two groups. 
Results A total of 177 patients were analyzed including 74 sublobar resections and 103 lobectomies with a 
total of 857 person-years of follow-up. R1 resection rate was 7% and 1% after sublobar resection and 
lobectomy, respectively (p=0.08). One of 5 patients with sublobar R1 resection developed recurrence. 
Recurrence rate was 0.02 (95%CI:0.009-0.044) per person year of follow-up after sublobar resection and
0.008 (95%CI:0.003-0.02) after lobectomy (p=0.15). Five-year survival rates were 91.7% (95%CI:78.5-
96.9%) and 97.4% (95%CI:90.1-99.4%) after sublobar and lobar resection respectively (p=0.08). Extent 
of resection was not a predictor of recurrence or survival. Propensity score analysis confirmed a similar 
survival and freedom from recurrence between the two groups. 
Conclusions Sublobar resection of peripheral cT1-3N0M0 pulmonary typical carcinoid was not associated 
with worse short or long-term outcomes compared to lobectomy. In select patients, sublobar resection may
be considered for treatment of peripheral typical carcinoids if an R0 resection is obtained.  
 















Typical carcinoids (TC) of the lung are low-grade tumors characterized by a neuroendocrine morphology 
and differentiation [1]. They are rare and indolent with a low rate of lymph node and distant metastases at 
presentation (5-15% and 3% respectively), limited rate of recurrence after surgical resection (2-9%) and 
excellent long-term survival (5-year survival rate >90% after surgery) [2-4]. According to the NCCN 
guidelines, the standard of care for pulmonary TC is anatomic resection but their optimal operative 
management is still debated [5]. 
 
For TC that are predominantly endoluminal and confined to the airway there is a general consensus that 
treatment with a bronchial sleeve resection with negative margins with the aim of sparing lung tissue is an 
acceptable oncologic operation. However, for peripheral TC, a similar rationale for limited parenchymal 
sparing resection, in the form of wedge resection or segmentectomy, is not generally applied. Therefore, 
the role of parenchymal sparing resection for peripheral TC remains controversial [6-9]. Recent evidence 
is based on studies of limited numbers or administrative data without the necessary granularity to be 
conclusive. Additionally, there are no randomized controlled trials targeting this topic and the rarity of this 
disease (< 5% of all lung cancers) precludes such a study design [6-8]. 
 
This study aims to compare rates and patterns of recurr nce and overall survival of patients undergoin 
sublobar resection versus lobectomy for clinical T1-3N0M0 peripheral TC of the lung. We hypothesize 
that sublobar resection results in similar survival and recurrence rates compared to lobectomy. 
 
Patients and Methods 
We retrospectively reviewed a multi-institutional series of consecutive patients who underwent curative 
lung resection for pulmonary TC between 2000-2015. Participating institutions included Swedish Cancer 
Institute (Seattle, WA), UC Davis Health (Sacramento, CA), Catholic University ‘Sacred Heart’ (Rome, 
Italy), San Giovanni Battista Hospital (Torino, Italy), University of Insubria-Ospedale di Circolo (Varese, 















(Everett, WA) and Virginia Mason Hospital and Medical Center (Seattle, WA). Patients with clinical T4 
and/or N1-2 and/or M1 disease, central tumor locatin and those with less than 1 month of follow-up were 
excluded from the study. Central tumors are those that can be visualized via bronchoscopy or associated 
with atelectasis and/or obstructive pneumonia, whereas peripheral tumors are those not visualized via 
bronchoscopy [9]. The institutional review board at e ch center approved this study and de-identified data
were transmitted between centers. Individual patient co sent was waived due to the retrospective nature of 
the study. 
 
For each patient, we collected the following data: age, sex, smoking history (current/former/never 
smoker), Eastern Cooperative Oncology Group (ECOG) performance status, forced expiratory volume in 
1 second (FEV1), previous malignancy, presence of symptoms at diagnosis (patients with respiratory 
symptoms, thoracic pain and /or carcinoid syndrome were considered symptomatic), preoperative imaging 
and biopsies, clinical 7th edition TNM stage, surgical reports, postoperative complications, pathological 
findings, induction/adjuvant therapy and follow-up. Standardized definitions for each data point were 
decided a priori based on previous literature and distributed to each center for use. 
 
Patients were divided into two groups based on the ext nt of resection: sublobar and lobar resection. 
Patients undergoing sublobar resection either underwent wedge resection or segmentectomy. Patients’ 
clinical pathological characteristics, postoperative complications, rate and pattern of recurrence, 
recurrence-free interval and overall survival were compared between the two groups. 
 
Cox regression modeling was performed to identify factors predicting overall survival and recurrence. 
Factors analyzed were age, sex, smoking history, ECOG performance status, FEV1, previous malignancy, 
presence of symptoms at diagnosis, extent of lung resection, lymphadenectomy, tumor size and clinical 
tumor stage (cT). Pathologic N and stage were excluded from these analyses because approximately half 
















Because there were factors that may have influenced surgeons’ decision on the extent of surgical 
resection, we performed a propensity matched analysis a  a sensitivity analysis using the following 
parameters for matching: age, gender, smoking history, ECOG performance status, previous malignancy, 
presence of symptoms at diagnosis, FEV1 and tumor size. Patients (n=29) without one of these data points 
were excluded from this analysis. Overall survival and recurrence-free interval were analyzed and 
compared in the matched cohort. 
 
Continuous data were reported as median with interquartile range (IQR) and compared using Mann–
Whitney U test. Categorical and count data were presented as frequencies and percentages and compared 
using Chi-square test or Fisher’s exact test if any expected frequency was less than 5. Overall survival was 
defined as time interval in months from date of surgery until last follow-up or date of death. Recurrenc -
free interval was defined as time interval in months from date of surgery until date of tumor recurrence. 
Incidence rates and confidence intervals were estimated using a Poisson model. Overall survival and 
recurrence-free interval were calculated using Kaplan-Meier estimates. For overall survival, univariate nd 
multivariate analyses were completed using Cox regression modeling stratified by site. For recurrence-fre  
survival, competing risks Cox regression models, stratified by site, were fit where death was considere  
the competing risk. The complementary models considering death as the event of interest with recurrence 
as the competing risk were also fit [10]. In multivariate analyses, we included extent of resection and any 
significant factors from univariate analyses. A p-value <0.05 was considered statistically significant. 
Statistical analyses were undertaken using SAS 9.4 (Cary, NC). Cumulative incidence curves for the 
competing events analyses were fit using the R functio  ‘cuminc’. Propensity score matching analysis was 
done using R function ‘matchit’ and standardized differences between the lobar and sublobar groups were

















Between 2000-2015, 365 patients underwent curative lung surgery for primary lung TC. A total of 188 
cases (patients with cT4 and/or cN1-2 and/or M1 disease or central tumor or follow-up <1 month) were 
excluded from the study. In the remaining 177 patients used for analysis, 26% (46/177) were male and the 
median age was 62 (IQR:54-70) years. Preoperative stage was assigned based on the available imaging 
studies in 165 patients (49 computed tomography scan alone, 116 computed tomography and somatostatin 
receptor scintigraphy and/or fluorodeoxyglucose positron emission tomography), by additional 
endobronchial ultrasound-guided transbronchial needle aspiration in 2, and by additional mediastinoscopy 
or other surgical biopsy in 10. 166 patients had clinical stage I disease and 11 stage II. All patients 
underwent resection with 75% (133/177) of cases undergoing lymph node sampling/lymphadenectomy. 
Sublobar resection was performed in 74 (20 segmentectomies and 54 wedge resections) (42%) cases and 
lobectomy in 103 (58%). No significant differences in terms of extent of parenchymal or lymph node 
resection were observed over the time period (2000-2005 vs 2006-2010 vs 2011-2015) (p=0.69 and 
p=0.24, respectively). The only significant differenc  was the higher rate of minimally invasive 
approaches (video/robotic-assisted thoracic surgery) performed after 2010 (p=0.003). 
 
Patients’ demographic and clinical pathological characteristics are listed in Table 1. Patient characteristics 
were similar between the two groups, except for higher rate of previous malignancy, lower FEV1, higher 
rate of R1 resection and smaller tumor size in the sublobar versus the lob ctomy group (Table 1). 
 
There was no postoperative mortality in either group. Postoperative morbidity was significantly higher in 
the lobectomy group: 23% (24/103) versus 7% (4/73) respectively (p=0.001). The most frequent 
complications in the lobectomy group were arrhythmia (6 patients), recurrent pleural effusion (3 patients) 
and major bleeding requiring reoperation (2 patients). In the sublobar resection group the most frequent 
complication was pneumothorax post chest tube removal (2 patients). Postoperative length of stay was 
significantly longer for the lobectomy group compared to the sublobar group: 6 (IQR: 4-9) versus 3 (IQR: 
















Total person-years of follow-up was 857. In the sublobar group, 6 recurrences in 301 person-years of 
follow-up were observed to yield a recurrence rate of 2.0 (95%CI: 0.9-4.4) per 100 person-years. 
Recurrence was local in 5/74 (6.8%) patients and systemic in 1/74 (1.4%) (liver). Of the 5 patients with a 
local recurrence 2 had wedge resection with no lymph node sampling/lymphadenectomy and 3 
segmentectomy with lymph node sampling. The treatmen  of local recurrence in these 5 patients was 
completion lobectomy in 1, biologic therapy with somatostatin analogues in 2, 1 was not treated due to 
poor performance status and 1 was not specified. Patient with systemic recurrence received chemotherapy. 
Clinical and pathological characteristics of these patients are listed in Table 2. 
 
In the lobectomy group, 4 recurrences in 508 person-years of follow-up were observed to yield a 
recurrence rate of 0.8 (95%CI: 0.3-2.1) per 100 person-years. All recurrences were systemic (1 liver, 1 
bone, 1 contralateral lung, 1 ipsilateral pleura). In all cases lymph node sampling was performed. Of the 4 
patients with recurrence treatment was chemotherapy (1), radiotherapy (1), one was not treated due to 
poor performance status and one was not specified. Clinical and pathological characteristics of these 
patients are listed in Table 2. 
 
Although recurrence rate was slightly higher in thesublobar than in the lobectomy group, the difference 
was not statistically significant (p=0.15). Moreover, recurrence-free interval was also similar when 
comparing the two groups [5-year: 88.5% (95%CI: 79.6-98.4%) and 98.7% (95%CI: 96.1-100%) for the 
sublobar and the lobectomy group respectively; p=0.12]. Univariate analyses showed that none of the 
covariates were independent predictors of recurrence when death was a competing risk whereas age and 
gender were independent predictors of death when recurrence was a competing risk (Table 3; Figure 1). 
 
During follow-up, 13/177 (7.3%) patients died. The causes of death were disease related in 2 patients and 















lobectomy group [5-year survival rate: 91.7% (95%CI: 78.5-96.9%) and 97.4% (95%CI: 90.1-99.4%) 
respectively; p=0.07; Figure 2]. On univariate analyses, age correlated with overall survival (Table 4). On 
multivariate analyses, age remained as significant predictor of overall survival after controlling for the 
extent of resection. 
 
A total of 153 patients were eligible for the propensity score matching analysis. The matched sample 
included 114 patients: 57 from the sublobar and 57 from the lobectomy group. Demographic and clinical 
characteristics of the matched cohort are listed in Table 5. The propensity score matched analysis showed 
no difference in recurrence-free interval and overall survival between patients undergoing sublobar 
resection and lobectomy. Specifically, 5-year recurrence-free survival was 92.4% (95%CI: 76.2-97.7%) 
and 100.0% (95%CI: 100.0-100.0%), respectively, for patients undergoing sublobar resection and 
lobectomy; p=0.57. Whereas, 5-year overall survival rate was 92.9% (95%CI: 79.4-97.7%) and 95.1% 
(95%CI: 81.5-98.8%), respectively, for patients undergoing sublobar resection and lobectomy; p=0.26. 
 
Comment 
The primary finding of this study is there was no stati tically significant difference in recurrence-fr e and 
overall survival between patients undergoing sublobar resection and lobectomy for cT1-3N0M0 peripheral 
TC. We had hoped that by using a large multi-centerd, international study methodology, we could 
overcome the issues of a rare disease with infrequent death rates to provide more granular data to address 
the question of appropriateness of sublobar resection in select patients with peripheral, TC. Unfortunately, 
the low rate of death and recurrence-free survival, limited the statistical power to provide a conclusive 
answer.  
 
Nevertheless, our results are similar to those report d by several prior studies that concluded that sublobar 
resection in the management of TC did not compromise survival and that lobectomy was not superior. 















resection over two different time frames and demonstrated 5-year survival rates over 80% in both studies 
[6-7]. However, these studies included a minority of atypical carcinoid tumors, extended resections and 
higher clinical stages where sublobar resection maynot be utilized. Moreover, neither study was able to 
focus solely on peripheral lesions, which are most amenable to sublobar resection and this likely result d 
in lower survival compared to our cohort. An older multi-institutional study also concluded that sublobar 
resection was appropriate but only included 22 wedge resections and no segmentectomies and reported a 
5-year survival rate of 82% [14]. Lastly, a recent best evidence topic reviewed the literature and showed 
that sublobar resection resulted in similar survival and concluded that there was little evidence to support 
the role of lobectomy over sublobar resection for TC [8]. 
 
One of our key concerns with sublobar resection wasth t the observed recurrence rate was higher 
compared to lobectomy. We assumed that all of our lcal recurrences occurred along the staple line in 
patients undergoing either wedge resection or segmentectomy with an R1 resection. However, this was not 
the case. Obviously, an incompletely resected tumor (R1) creates a risk for local recurrence and a wider 
resection should be considered in this situation. Our recurrence pattern also suggests that the presenc  of 
N1 or N2 positive nodes and the presence of additional tumor nodules are also risk factors for local 
recurrence. Had these patients undergone completion lobectomy, the overall recurrence rate after sublobar 
resection drops from 6.8% to 2.7% (1 local and 1 systemic recurrence), which is similar to the recurrence 
rate (3.9%) of the lobectomy group. 
 
The other consideration in selecting sublobar resection is tumor size. Even though our analysis did not 
identify tumor size or cT as independent risk factor for survival or recurrence, tumor size and location can 
influence a surgeon’s decision to perform sublobar resection. In our series, patients undergoing sublobar 
resection had median tumors size of 1.2 cm with an IQR of 1.0-1.6 cm. This suggests that sublobar 
resection may be selected as an option when the neoplasm is less than 2.0 cm. While, no other data 















non-small cell lung cancer comparing sublobar resection vs lobectomy (CALGB 140503) [15]. It might be 
feasible to consider a slightly larger tumor size of 3 cm or less but this may push the limits of sublobar 
resection depending on which lobe and the tumor’s exact location. It is the combination of a typical or 
low-grade neuroendocrine histology with a tumor size of less than 3 cm that has been shown to have 
similar survival in a recent analysis investigating carcinoid staging [4]. 
 
Sublobar resection is a reasonable option for select patients with peripheral TC tumors because our data
suggest that a sublobar approach is not associated wi h worse recurrence-free interval or overall survival 
compared to lobectomy. So, who might be an ideal candid te for sublobar resection? One possible option 
is to utilize the factors in the ESTS prognostic model for TC to inform such a decision [16]. Older patients 
with a prior history of malignancy and reduced performance status with a small peripheral lesion may be 
best suited to undergo sublobar resection as this provides a balance with their other risks. However, the 
model also suggests that a young healthy female pati nt with no history of smoking or cancer with a small 
lesion has an excellent survival regardless of the ext nt of resection. One challenge in choosing a patient 
for sublobar resection is the lack of concordance between preoperative biopsy/frozen session and final
pathology. In the presence of a peripheral solitary lesion, a reasonable approach is to consider a wedge 
resection or sublobar resection and await final pathology in order to preserve lung parenchyma [1]. This 
requires informing the patient about the possibility of returning to the operatory room for a completion 
lobectomy if the final pathology evaluation reveals typical carcinoid histology and the patient is fit for a 
greater resection. In our experience, most patients, when presented with this possibility, will chose th  
initial limited resection approach, favoring possible lung preservation.    
 
This study has several limitations. First, the numbers of recurrences and of deaths are infrequent and his 
limits the power to detect a statistically significant difference between the two types of resections. To be 















Second, this is a retrospective study with all the limitations inherent to this study design, even though, all 
centers accurately reviewed each record to document th  course of every patient in detail and minimize 
missing data. Moreover, before starting the data colle tion we built a common database defining each 
record. Third, a centralized review process for pathology was not available. However, all the results were 
reviewed in each center, which provides more granular data than an administrative data study. Lastly, a 
major strength of our study is that we report not only survival but also recurrence, completeness of 
resection and postoperative complications, leading to a more complete comparison between sublobar 
resection and lobectomy. 
 
Sublobar resection of peripheral cT1-3N0M0 pulmonary TC results was not associated with worse 
surgical outcomes, freedom from recurrence or overall survival compared to lobectomy. Patients with 
positive regional lymph node(s) or additional tumor n dules and/or involvement of the surgical margins 
should be considered for lobectomy whenever feasible.  In select patients, sublobar resection may be a
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Median age, year (IQR) 63(54-70) 62(54-71) 0.31 
Male, n (%) 16(22) 30(29) 0.26 
Current/former smoker, n (%) 33(45)a 50(47) 0.66 
ECOG performance status, n (%)   0.59 
  0 58(78) 86(84)  
  1 11(15) 13(12)  
  >2 5(7) 4(4)  
Median FEV1, % (IQR) 89(74-105)
b 98(83-113)c 0.03 
Previous malignancy, n (%) 20(27)a 14(14)a 0.15 
Symptoms at diagnosis, n (%) 25(34) 46(45) 0.13 
Lymphadenectomy/sampling, n (%) 39(53) 94(94) <0.001 
Median tumor size, cm (IQR) 1.2(1.0-1.6) 2.0(1.5-3.0) <0.001 
cT Status, n (%) a  <0.001 
  cT1 78(76) 66(89)  
  cT2 22(22) 2(3)  
  cT3 2(2) 6(8)  
cN Status, n (%) a   
  cN0 102(100) 74(100)  
Clinical Stage, n (%) a  0.21 
  I 98(96) 67(91)  
  II  4(4) 7(9)  















  pT1 64 (87) 79 (77)  
  pT2 3 (4) 20 (20)  
  pT3 6 (8) 3 (3)  
  pT4 1 (1) 0  
Completeness of resection, n (%)  a 0.09 
  R0 69(93) 101(99)  
  R1 5(7)d 1(1)  
pN Status, n (%) e f 0.99 
  pN0 35 (90) 84 (90)  
  pN1 3 (8) 6 (6)  
  pN2 1 (3) 3 (3)  
Pathological stage, n (%) e f 0.47 
  I 31(80) 79 (85)  
  II  5(13) 11(12)  
  III  3(8) 3(3)  
IQR=interquartile range; ECOG=Eastern Cooperative Oncology Group; FEV1=forced expiratory volume 
in 1 second; a=data not available in 1 patient; b=data not available in 15 patients; c= data not available in 
11 patients; d=4 wedge resection, 1 segmentectomy; e=data not available in 35 patients who did not have 
lymph node sampling/lymphadenectomy; f=data not available in 9 patients who did not have lymph node 
















Table 2 Clinical and pathological characteristics of patients with recurrent disease. 
 Patients Recurrence FEV1,% R Tumor size, cm pT pN 
Sublobar 1 Locala 76 R1 0.9 pT1a pNX 
resection 2 Localb n.a. R0 1.6 pT1a pN0 
group 3 Localb 104 R0 1.8 pT1a pN2 
 4 Localb n.a. R0 1.0 pT1a pN1 
 5 Localb 59 R0 1.1 pT3c pNX 
 6 Systemic n.a. R0 1.4 pT1a pNX 
Lobectomy 1 Systemic 72 R0 2.4 pT1b pN0 
group 2 Systemic n.a. R0 6.0 pT2b pN0 
 3 Systemic n.a. R0 3.4 pT2a pN0 
 4 Systemic 143 R0 0.5 pT1a pN1 
FEV1=forced expiratory volume in 1 second; R=completeness of resection; n.a.=data not available; 
a=the 
tumor recurred along surgical margins; b=the tumor recurred in the same lobe; c=2nd separate tumor nodule 
















Table 3 Factors influencing recurrence and death: univariate Cox regression models stratified by site with 
death as a competing risk and recurrence as a competing risk, respectively. 
 
Recurrence 
(death as competing risk) 
Death 
(recurrence as competing risk) 
 HR (95%CI) p-value HR (95%CI) p-value 
Age (continuous) 1.02 (0.96-1.08) 0.56 1.10 (1.05-1.15) <.0001 
Gender (Reference=Female) 0.30 (0.04-1.99) 0.21 3.02 (1.03-8.79) 0.04 
Smoking history (Reference=Non-Smoker) 0.55 (0.13-2.40) 0.43 1.51 (0.46-4.93) 0.49 
ECOG performance status >1 (reference 0) 1.74 (0.32-9.41) 0.52 3.94 (0.96-16.12) 0.06 
FEV1 (continuous) 0.98(0.95-1.02) 0.27 0.99 (0.95-1.03) 0.71 
Previous malignancy (Reference=No) 2.26 (0.59-8.60) 0.23 1.11 (0.23-5.28) 0.9 
Symptoms (Reference=No) 0.66 (0.19-2.33) 0.51 1.27 (0.40-4.06) 0.68 
Extent of resection (Reference=Lobar) 1.82 (0.54-6.13) 0.33 2.10 (0.71-6.23) 0.18 
Lymphadenectomy/Sampling (no vs yes) 0.34 (0.04-2.65) 0.30 0.41 (0.11-1.50) 0.18 
Tumor size (continuous) 1.01(0.69-1.46) 0.97 0.99 (0.62-1.60) 0.98 
cT2-3(reference=cT1) 1.14 (0.32-3.97) 0.84 1.90 (0.53-6.86) 0.32 
HR=hazard ratio; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; FEV1=forced 















Table 4 Factors influencing overall survival: univariate Cox regression models stratified by site. 
Factors 
Univariate analysis 
HR (95%CI) p-value 
Age (continuous) 1.12 (1.05-1.20) <0.001 
Gender (Reference=Female) 2.34 (0.72-7.61) 0.16 
Smoking history (Reference=Non-Smoker) 1.50 (0.50-4.51) 0.47 
ECOG Performance Status >1 (reference 0) 3.31 (0.80-13.71) 0.10 
FEV1 (continuous) 0.99 (0.96-1.02) 0.44 
Previous malignancy (Reference=No) 1.44 (0.38-5.40) 0.59 
Symptoms (Reference=No) 0.97 (0.31-3.00) 0.96 
Extent of resection (Reference=Lobar) 2.77 (0.87-8.76) 0.08 
Lymphadenectomy/Sampling (Reference=No) 0.30 (0.07-1.29) 0.10 
Tumor size (continuous) 0.78 (0.43-1.42) 0.41 
cT2-3(reference=cT1) 1.61 (0.42-6.18) 0.84 
HR=hazard ratio; CI=confidence interval; ECOG=Eastern Cooperative Oncology Group; FEV1=forced 
















Table 5 Demographic, clinical and pathological characterisics of the matched cohort with standardized 















Mean age, year (SD) 58.9 (18.3) 61 (10.6) 0.14 0.05 
Male, n (%) 15 (26) 20 (35) 0.19 0.17 
Current/former smoker, n (%) 25 (44) 28 (49) 0.11 0.07 
ECOG performance status, n (%)   0.10 0.15 
0 44 (77) 46 (81)   
1 10 (18)  8(14)   
>2 3 (5) 3 (5)   
Mean FEV1, % (SD) 89.5 (25) 94.3 (23.2) 0.20 0.37 
Previous malignancy, n (%) 15 (26) 11 (19) 0.17 0.34 
Symptoms at diagnosis, n (%) 35 (28) 51 (39) 0.23 0.22 
Mean tumor size, cm (SD) 1.3 (0.6) 1.6 (0.5) 0.47 0.95 
aStandardized difference = (X2 X1)/((S2 
2 + S1 
2 )/2)1/2, X1 and X2 are samples means in the sublobar and 
lobar groups respectively, and S2 
2 and S1 

















Figure 1 Cumulative incidence estimates for competing risks of recurrence (a) and death (b). 
Figure 2 Kaplan-Meier estimates for overall survival. 
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